Biovail Partners with Alexza On Late-Stage CNS Drug For Schizophrenia Agitation
This article was originally published in The Pink Sheet Daily
Executive Summary
Biovail gets ready to rebuild a U.S. commercial team, while Alexza gets a cash infusion to fund its business through early 2011.